| Literature DB >> 21152049 |
He Jun1, Chen Daiwen, Yu Bing.
Abstract
Starch is one of the major dietary energy sources for mammals. However, the nutritional value of starch largely depends on its amylose and amylopectin ratio. In this study, the overall metabolic and transcriptomic responses of weaned pigs fed with different dietary starches were assessed. Sixteen weaned pigs were randomly allotted to two experimental diets containing either of pure cassava starch (CS) or maize starch (MS) as the sole energy source (the amylose-amylopectin ratio were 0.25 and 0.43, respectively). Results indicated that the body weight gain was not affected by different dietary starches. However, a moderate fatty liver was observed in CS-fed group. Long-term ingestion of CS not only increased the total liver fat content, but significantly elevated the liver triglyceride and cholesterol content (P<0.05). In addition, the serum insulin and cholesterol concentrations were both elevated in CS-fed group (P<0.05). Microarray analysis led to the identification of 648 genes differentially expressed in liver (P<0.05), and a lot of them were involved in lipid and carbohydrate metabolism. Additionally, pathway analysis indicated that both the insulin and PPAR signaling pathways were acutely affected by dietary amylose-amylopectin ratio. Long-term ingestion of CS activated the transcription of lipogenic genes such as hmgr and fasn, but decreased the expression of lipolytic genes such as aox1, ppara and fbp. The microarray results correlated well with the measurements of several key enzymes involved in hepatic lipid metabolism. Our results suggested that both the metabolic and transcriptomic responses of weaned pigs were tightly regulated by dietary starch composition, and a high amylose ratio starch (i.e MS) may be more healthful for mammals as the long-term energy source by down-regulation of hepatic lipogenesis and steroidogenesis.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21152049 PMCID: PMC2994909 DOI: 10.1371/journal.pone.0015110
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Composition of experimental diet (as fed-basis).
| Ingredients | % of diet |
| Cassava or maize starch | 54.50% |
| Dehulled soybean meal | 2.00% |
| Extruded soybean | 10.00% |
| Soy protein concentrate | 17.83% |
| Whey powder | 7.30% |
| Fish meal | 6.00% |
| CaHPO4 | 0.70% |
| CaCO3 | 0.55% |
| Salt | 0.15% |
| Choline Chloride (50%) | 0.10% |
| L-Lysine | 0.00% |
| Methionine+Cysteine | 0.17% |
| Threonine | 0.01% |
| Cr2O3 | 0.40% |
| Trace mineral premix | 0.20% |
| Vitamin premix | 0.04% |
| Additives | 0.05% |
|
| 100.00% |
Supplied (per kg diet): Fe as FeSO4.7H2O, 100 mg; Mn as MnSO4.7H2O, 40 mg; Zn as ZnO, 80 mg; Cu as CuSO4.5H2O, 10 mg; Se as NaSeO3, 0.3 mg; and I as KI, 0.3 mg.
Supplied (per kg diet): 19,000 IU vitamin A, 36.65 IU vitamin E, 386 IU vitamin D, 1.1 mg vitamin K (menadione dimethylpyrimidinoe bisulfate), 5 mg vitamin B1, 15 mg riboflavin, 25 mg niacin, 30 mg d-pantothenic acid, and 0.05 mg vitamin B12.
Primer sequences of genes selected for analysis by real-time RT-PCR.
| Gene | Accessionnumber | Forward primer | Reverse primer | Temp(°C) |
|
| NM_001097461 |
|
| 62.0 |
|
| NM_001044571 |
|
| 60.6 |
|
| NM_001143727 |
|
| 59.5 |
|
| NM_213825 |
|
| 56.9 |
|
| NM_001122988 |
|
| 60.5 |
|
| AK232470 |
|
| 59.1 |
|
| NM_001099930 |
|
| 59.5 |
|
| NM_001129805 |
|
| 59.5 |
|
| NM_213979 |
|
| 60.8 |
|
| NM_214276 |
|
| 59.8 |
|
| AK232864 |
|
| 58.5 |
|
| NM_214051 |
|
| 59.6 |
|
| AY550069 |
|
| 56.5 |
Gene abbreviations: socs2, suppressor of cytokine signaling 2; hnf4a, hepatocyte nuclear factor 4; mst4, serine/threonine protein kinase MST4; galp, galanin-like peptide; hmgr, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; acox1, acyl-Coenzyme A oxidase 1; fasn, fatty acid synthase; cpt1a, carnitine palmitoyltransferase 1A; fbp, secreted folate binding protein; cs, citrate synthase; ppara, peroxisome proliferator-activated receptor alfha; dgat, diacylglycerol acyltransferase; srebp1c, sterol regulatory element-binding protein 1c.
Influences of dietary amylose-amylopectin ratio on growth performance, serum metabolite and hormone concentrations.
| Parameter | Cassava starch | Maize starch |
|
| ||
| Average daily gain (g/d) | 378.9±21.3 | 386.7±28.2 |
| Average daily intake (g/d) | 492.7±29. 1 | 509.4±35.6 |
|
| ||
| Serum glucose (mmol/L) | 6.83±0.48 | 6.40±0.34 |
| Serum triglyceride (mmol/L) | 0.54±0.02 | 0.47±0.03 |
| Serum cholesterol (mmol/L) | 2.04±0.13 | 1.54±0.10 |
| Liver total fat ( | 8.91±0.62 | 5.38±0.33 |
| Liver triglyceride (µmol/g) | 69.12±7.11 | 58.34±6.32 |
| Liver cholesterol (µmol/g) | 3.42±0.25 | 2.78±0.19 |
|
| ||
| GH (ng/mL) | 1.03±0.04 | 0.92±0.03 |
| Insulin (pmol/L) | 72.42±5.93 | 56.24±5.17 |
| Glucagon (pg/mL) | 31.33±6.12 | 26.51±5.74 |
|
| ||
| Glucose-6-phosphate dehydrogenase | 35.16±2.91 | 33.25±2.42 |
| Fatty acid synthetase | 28.56±2.74 | 23.38±2.15 |
| Acyl-CoA oxidase | 3.61±0.42 | 4.46±0.35 |
| HMG-CoA reductase | 6.2±0.51 | 4.9±0.38 |
Note:
means P<0.05;
means P<0.01.
Comparison of the microarray and real-time RT-PCR results.
| Gene | Microarray results | Real-time PCR results | Regulation | ||
| P value | Fold change | P value | Fold change | ||
|
| # | 1.30 | * | 1.05 | + |
|
| # | 1.08 | # | 1.22 | - |
|
| * | 2.07 | * | 1.78 | + |
|
| ** | 3.21 | # | 1.04 | - |
|
| ** | 1.35 | ** | 1.62 | - |
|
| ** | 1.12 | * | 1.32 | + |
|
| ** | 1.11 | ** | 1.09 | - |
|
| # | 1.11 | # | 1.06 | - |
|
| # | 1.05 | * | 1.29 | + |
|
| # | 1.05 | # | 1.11 | - |
|
| * | 1.07 | * | 1.25 | + |
|
| # | 1.10 | # | 1.01 | + |
Results based on hybridization of 8 microarrays using 8 pooled samples.
Results based on 16 individual samples.
The regulation was basis on the real MS/CS ratio from real-time PCR assay. (+) means the fraction (MS/CS) was more than 1 (up-regulation), whereas (−) means the fraction is under 1 (down-regulation).
Note: *means P<0.05; **means P<0.01; #means P>0.05.
Pathways containing significant numbers of differentially expressed genesa.
| Pathway | Hits | Total | Percent | P value |
| Alanine and aspartate metabolism | 2 | 13 | 15.38% | 0.0389 |
| Antigen processing and presentation | 7 | 42 | 16.67% | 0.0001 |
| Arachidonic acid metabolism | 5 | 30 | 16.67% | 0.0008 |
| Autoimmune thyroid disease | 3 | 32 | 9.38% | 0.0371 |
| Calcium signaling pathway | 6 | 71 | 8.45% | 0.0057 |
| Cardiac muscle contraction | 5 | 32 | 15.63% | 0.001 |
| Cell adhesion molecules (CAMs) | 8 | 57 | 14.04% | 0.0001 |
| Citrate cycle (TCA cycle) | 2 | 17 | 11.76% | 0.05 |
| Drug metabolism - cytochrome P450 | 3 | 24 | 12.50% | 0.0187 |
| ErbB signaling pathway | 3 | 32 | 9.38% | 0.0371 |
| Focal adhesion | 8 | 73 | 10.96% | 0.0003 |
| Glutathione metabolism | 3 | 22 | 13.64% | 0.0152 |
| Graft-versus-host disease | 3 | 25 | 12.00% | 0.0206 |
| Hematopoietic cell lineage | 4 | 48 | 8.33% | 0.0238 |
| Insulin signaling pathway | 5 | 47 | 10.64% | 0.0223 |
| Leukocyte transendothelial migration | 5 | 44 | 11.36% | 0.0036 |
| Long-term depression | 4 | 33 | 12.12% | 0.0074 |
| Long-term potentiation | 3 | 24 | 12.50% | 0.0187 |
| Metabolism of xenobiotics by cytochrome P450 | 3 | 21 | 14.29% | 0.0136 |
| mTOR signaling pathway | 2 | 15 | 13.33% | 0.0491 |
| PPAR signaling pathway | 5 | 48 | 10.42% | 0.0238 |
| Purine metabolism | 6 | 44 | 13.64% | 0.0006 |
| Regulation of actin cytoskeleton | 6 | 66 | 9.09% | 0.0041 |
| Type I diabetes mellitus | 3 | 32 | 9.38% | 0.0371 |
| Type II diabetes mellitus | 2 | 15 | 13.33% | 0.0491 |
Selected from KEGG pathway database (http://www.genome.jp/kegg/pathway.html).
Figure 1Influence of dietary amylose-amylopectin ratio on insulin (A) and PPAR (B) signaling pathways.
(a) Ketogenesis, (b) Lipid transport, (c) Lipogenesis, (d) Cholesterol metabolism, (e) Fatty acid transport, (f) Fatty acid oxidation, (g) Adipocyte differentiation, (h) Gluconeogenesis; Gene symbols in red indicate genes that are differentially expressed.